Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Company Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. In oncology, its marketed medicines include Vyxeos® (daunorubicin and cytarabine liposome) for newly diagnosed therapy-related acute myeloid leukemia, Zepzelca® (lurbinectedin) for small cell lung cancer, and Defitelio® (defibrotide) for hepatic veno-occlusive disease. Through the acquisition of GW Pharmaceuticals in 2021, Jazz added Epidiolex® (cannabidiol) to its portfolio for rare epilepsy syndromes.

Founded in 2003 and headquartered in Dublin, Ireland, Jazz maintains research, development and commercial operations across North America, Europe and Asia-Pacific. The company expanded its capabilities through a series of strategic mergers and acquisitions, including the 2011 combination with Azur Pharma and the 2021 purchase of GW Pharmaceuticals, strengthening its position in both neurology and oncology.

Under the leadership of President and Chief Executive Officer Bruce C. Cozadd, Jazz Pharmaceuticals continues to advance its clinical pipeline with investigational candidates in sleep disorders, neurodevelopmental conditions and various cancer indications. The company emphasizes global collaboration and strategic partnerships to accelerate the delivery of novel therapies to patients worldwide.

Key Stats

• Today's Range: $128.50 to $130.08
• 50-Day Range: $105.93 to $131.72
• 52-Week Range: $95.49 to $148.06
• Volume: 274,914 shs
• Average Volume: 683,791 shs
• Market Capitalization: $7.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $178.93
• Consensus Rating: Moderate Buy

Jazz Pharmaceuticals Stock Analysis - MarketRank™

Jazz Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 117th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Jazz Pharmaceuticals has a consensus price target of $178.93, representing about 38.1% upside from its current price of $129.59.

Amount of Analyst Coverage

Jazz Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.32%

Earnings Growth

Earnings for Jazz Pharmaceuticals are expected to grow by 10.32% in the coming year, from $16.96 to $18.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jazz Pharmaceuticals is -19.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jazz Pharmaceuticals is -19.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Jazz Pharmaceuticals has a PEG Ratio of 8.02. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Jazz Pharmaceuticals has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.89% of the float of Jazz Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Jazz Pharmaceuticals has recently increased by 1.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jazz Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Jazz Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.96

Percentage of Shares Shorted

9.89% of the float of Jazz Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Jazz Pharmaceuticals has recently increased by 1.60%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.79

News Sentiment

Jazz Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Jazz Pharmaceuticals this week, compared to 15 articles on an average week.

Search Interest

Only 15 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

MarketBeat Follows

5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $879,350.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Jazz Pharmaceuticals is held by insiders.

Percentage Held by Institutions

89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JAZZ Stock Analysis - Frequently Asked Questions

How have JAZZ shares performed this year?

Jazz Pharmaceuticals' stock was trading at $123.15 on January 1st, 2025. Since then, JAZZ shares have increased by 5.2% and is now trading at $129.59.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, August, 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by $2.64. The company's revenue for the quarter was up 2.1% on a year-over-year basis.
Read the conference call transcript.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion.

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' top institutional shareholders include LSV Asset Management (4.22%), State Street Corp (3.19%), Ameriprise Financial Inc. (3.08%) and JPMorgan Chase & Co. (2.84%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Mary Elizabeth Henderson, Samantha Pearce, Rick E Winningham, Patricia Carr, Mark Douglas Smith and Jennifer E Cook.
View institutional ownership trends.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/24/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:JAZZ
• CIK: 1232524
• Web: www.jazzpharma.com
• Phone: (531) 634-7800
• Fax: 353-1634-7850
• Employees: 2,800
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Jazz Pharmaceuticals: $178.93
• High Price Target: $217.00
• Low Price Target: $147.00
• Potential Upside/Downside: +38.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.60
• P/E Growth: 8.07
• Net Income: $560.12 million
• Net Margins: -9.91%
• Pretax Margin: -12.51%
• Return on Equity: 5.02%
• Return on Assets: 1.73%

Debt

• Debt-to-Equity Ratio: 1.17
• Current Ratio: 1.62
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $4.09 billion
• Price / Sales: 1.91
• Cash Flow: $30.03 per share
• Price / Cash Flow: 4.29
• Book Value: $67.72 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 60,659,000
• Free Float: 58,051,000
• Market Cap: $7.81 billion
• Optionable: Optionable
• Beta: 0.24